For women with advanced ovarian cancer in complete or partial response to platinum-based chemotherapy

ZEJULA may keep you moving forward.*

*In a first-line maintenance clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. Results may vary. The trial is ongoing to see if patients live longer overall with treatment.

If you’ve been recently diagnosed with advanced ovarian cancer, ZEJULA may be a next step in your path forward.

ZEJULA is the only once-daily oral first-line maintenance treatment for women with advanced ovarian cancer after responding to platinum-based chemotherapy.

Including fallopian tube or primary peritoneal cancer.
Complete or partial response.

Who can take ZEJULA (niraparib)?

In addition to first-line maintenance treatment, ZEJULA is also approved for 2 other groups of women with ovarian cancer.

Learn more and see results for ZEJULA as a:

First-Line Maintenance Treatment

Discover more

Recurrent Maintenance Treatment

Discover more

Late-Line Treatment in HRD+§ Patients

Discover more

§HRD, or homologous recombination deficiency, occurs when cells have difficulty repairing themselves and appears in about 50% of women with ovarian cancer.

What is

Maintenance

Therapy?

It could be an option for you or a loved one.

 

Ovarian cancer maintenance therapy is a treatment option that is given to delay the cancer from coming back after it has responded to platinum-based chemotherapy.

 

Learn more

Why ZEJULA?

Learn about the features of ZEJULA

01

ZEJULA is the only once-daily oral maintenance treatment for ovarian cancer.

Discover more

02

ZEJULA is an oral treatment that can be taken at any time of day that works for you, although it should be taken at approximately the same time each day.

How it works

03

As a maintenance therapy, ZEJULA offered more time without cancer recurring, regardless of certain genetic characteristics, like BRCA status.||

Read the data

||In a first-line maintenance clinical trial, ZEJULA delayed disease progression for a median of 14 months vs 8 months with placebo. Results may vary. Median is the middle number in a set of data, also called the midpoint. The trial is ongoing to see if patients live longer overall with treatment.

Ready for the

next step?

It’s time to talk to your doctor.

 

It’s important to know and understand your treatment options for ovarian cancer. Whether you’re just starting treatment now or your cancer has already recurred, you can start the conversation with your doctor to help decide if ZEJULA is right for you.

 

Start the conversation